September 30 – October 2, 2025 | Boston, MA
www.ipsc-therapies-summit.com

REGISTER BY JULY 11 AND SAVE UP TO $700!

WELCOME
EXPERT SPEAKERS
AGENDA
PARTNER WITH US
REGISTER YOUR PLACE

5th Annual

iPSC Drug Development Summit

Driving Stability, Clinical Validity & Scalable Production of iPSC Therapies

Enhance Cell Differentiation, Uncover Optimal Cell Line Starting Material & Drive Investor Confidence to Accelerate Clinically Successful iPSC Derived Therapies to Market

Expert Speakers Include:

Sherry Hikita
Project Director, Cell Therapy R&D
Novo Nordisk

Alex Ng
Co-Founder & Chief Scientific Officer
GC Therapeutics

Nina Horowitz
Chief Executive Officer
ImmuneBridge

Howard Federoff
Chief Medical Officer
Kenai Therapeutics

Alla Amcheslavsky
Senior Scientist Analytical Development
Astellas Pharma

Rajesh Thangapazham
Global Regulatory Strategy Lead
Vertex Pharmaceuticals

Catalent · Ajinomoto · PBS Biotech · Roslin CT · ThermoFisher Scientific · Lonza · Advanced Instruments · bit bio · Fujifilm Value from Innovation

+1 617 455 4188 info@hansonwade.com
www.ipsc-therapies-summit.com Cell & Gene Therapy Event Series
hansonwade

Welcome to the 5th Annual iPSC Drug Development Summit!

5th Annual iPSC Drug Development Summit
September 30 – October 2, 2025
Boston, MA

As the iPSC field rebounds from a challenging funding environment in 2024, a renewed wave of innovation, investment, and collaboration is reshaping its future. With **Aspen Neuroscience** advancing its Parkinson's trial and expanding GMP manufacturing, **Century Therapeutics** initiating clinical evaluation of iNK cells, and **BlueRock Therapeutics** entering a pivotal phase 3 study, the momentum is undeniable.

The **5th Annual iPSC Drug Development Summit** returns to Boston as your longest-standing and most definitive platform for uniting iPSC-based drug developers across the value chain, from R&D right through to CMC, to accelerate the development of genetically stable, clinically efficacious and scalable iPSC based therapies

With a disease-agnostic lens spanning oncology, neurology, cardiology, immunology, degenerative diseases and more this is the go-to forum to advance your iPSC expertise and chart a clearer path to late-stage clinical success.

Selin Ibrahimov
Senior Program Director

What Our Speakers Have to Say:

"iPSC-derived therapies are experiencing growing pains due to:

1. **High technical barriers**
2. **Rigid regulatory frameworks**
3. **High cost due to materials and complex manufacturing processes**

This meeting has been a great forum for leaders in this emerging field to exchange their experience of challenges old and new, and find novel solutions and synergies to collaborate and help each other. I found discussions in previous events more open and of real value."

Allen Feng, Founder & Chief Scientific Officer, **HebeCell**
Attended the iPSC Drug Development Summit every year since its launch

What *DIFFERENTIATES* the 5th iPSC Drug Development Summit?

The Only Meeting Where You Can:

Enhance understanding of starting cell line selection by exploring donor variability and predictive assays with **iPSirius** and **Thymmune Therapeutics**

Maximize the scalable expansion of high quality and consistent iPSC-derived cells by exploring 2D versus 3D platforms and integrating automation with **BlueRock** and **HebeCell**

Define necessary steps to advance into clinical development through enforcing GMP grade processes and meeting regulatory requirements with lessons learned from **Novo Nordisk** and a case study from **Century Therapeutics**

Advance immune reconstitution, cancer therapy and more by examining engineered iPSC-derived cells and allo-evasion technologies with **Lift Biosciences** and **Kenai Therapeutics**

How Has 2025 *REPROGRAMMED* as New?

5th Annual iPSC Drug Development Summit
September 30 – October 2, 2025
Boston, MA

2 New Tracks for 2 New *FATES*

From genetic engineering strategies to selecting the right culture conditions and reagents, the **Preclinical Development track** addresses all the challenges iPSC developers face before even entering clinic

Manufacturing at scale using the right equipment while assuring reproducibility and high-end cell quality is hard. The **Process Development & CMC track** tackles these challenges head on

Novel Workshops to Ensure you *MATURE* into the Desired Developer

De-risk your iPSC therapy from the start by refining your **starting cell line selection strategy** with **iPSIRIUS** and **Thymmune Therapeutics**. Unpack how donor variability, genomic stability, and predictive differentiation assays shape the safety, efficacy, and manufacturability of your iPSC-derived products

Drive standardization across the iPSC field by **aligning on QC testing and differentiation protocols** with **Aspen Neuroscience** and **Retro Biosciences**. Identify critical quality attributes, explore harmonized assay approaches, and evaluate current regulatory frameworks to identify where the iPSC industry can unite

"I believe that this workshop offers a unique opportunity to engage with peers and collaboratively address some of the critical CMC challenges that come with advancing the iPSC-derived cell therapies toward the clinic"

Yanzheng Liu, Senior Director of Quality Control, **Aspen Neuroscience, 2025 Speaker**

Lessons Learned & Practical Insights

Accelerate your path to clinic by learning from top pioneers

Defining Considerations When Transitioning Processes & Cell Lines from RUO to GMP

Sherry Hikita
Project Director, Cell Therapy R&D
Novo Nordisk

Case Study: Discussing the Regulatory Pathway to Clinic

Eric Law
Head of CMC Regulatory Affairs
Century Therapeutics

13 Brand-New Companies Joining the Agenda!

BlueRock Therapeutics · BroadOak Capital Partners · ErneXa Therapeutics · GC Therapeutics · ImmuneBridge · LIfT BioSciences · matricelf · ORGANAMET BIO · ORIZURU THERAPEUTICS · Retro BIOSCIENCES · Sana Biotechnology · STRATUS Therapeutics · VERTEX

+1 617 455 4188 info@hansonwade.com
www.ipsc-therapies-summit.com Cell & Gene Therapy Event Series
hansonwade

Your Expert Speakers

Jeffrey Kordower
Professor
Arizona State University

Yanzheng Liu
Senior Director Quality Control
Aspen Neuroscience

Alla Amcheslavsky
Senior Scientist CMC Analytica Development
Astellas Pharma

Lev Starikov
Senior Scientist Process Development
BlueRock Therapeutics

Angelos Oikonomopoulos
Principal Scientist Project Lead
Formerly BMS

Eric Law
Head of CMC Regulatory Affairs
Century Therapeutics

Jason Mills
Senior Director of Process Development
Century Therapeutics

Sanjeev Luther
Chief Executive Officer
Ernexa Therapeutics

Robert Pierce
Chief Scientific Officer
Ernexa Therapeutics

Jack Li
Director of Process Development
Stratus Therapeutics

Jay Sorensen
Vice President of Manufacturing
Stratus Therapeutics

Alex Ng
Co-Founder & Chief Scientific Officer
GC Therapeutics

Azadeh Golipour
Senior Vice President, Head of Technical Operations
GC Therapeutics

Ran Jing
Instructor
Harvard Medical School, Boston Children's Hospital

Nina Horowitz
Chief Executive Officer
ImmuneBridge

Daniel Friedman
Principal
Broad Oak Partners

Allen Feng
Founder & Chief Scientific Officer
HebeCell

Annelise Bennaceur
Chief Scientific Officer
iPSirius

Ali Turhan
Chief Medical Officer
iPSirius

Howard Federoff
Chief Medical Officer
Kenai Therapeutics

Mark Exley
Chief Scientific Officer
Lift Biosciences

Your Expert Speakers

Tal Dvir
Founder & Chief Scientific Officer
Matricelf

Sherry Hikita
Project Director, Cell Therapy R&D
Novo Nordisk

Doris Taylor
Co-Founder
Organamet

Naoyuki Tahara
Senior Scientist
Orizuru Therapeutics

Anastasia Shindyapina
Staff Scientist
Retro Biosciences

Panagiotis Douvaras
Head of CNS Biology
Retro Biosciences

Lina Sui
Senior Director Process & Analytical Development
Sana Biotechnology

Matt Buckley
Chief Executive Officer & Co-Founder
Theseus Therapies

Benjamin Schwarz
Associate Director
Thymmune Therapeutics

Rajesh Thangapazham
Global Regulatory Strategy Lead
Vertex Pharmaceuticals

Barbara Ressler
Vice President of Manufacturing Process Sciences
RoslinCT

Ali Darkazalli
Principal Scientist Process Development
RoslinCT

Dr. David Kuninger
Director, R&D
Thermo Fisher Scientific

> "I found speakers were interactive and open to discuss problems and potential solutions in developing iPSC drug products. Concerns about the safety and regulatory aspects of iPSC drug manufacturing discussions stood out most to me."
>
> Associate Principal Scientist, **AstraZeneca**, 2024 Speaker

Pre-Conference Workshop Day
Tuesday, September 30

Workshops include presentations with extended Q&As from each host, followed by audience-led discussions and key takeaways

Check-in & Coffee — **8.00**

Workshop A — 9.00 - 12.00

Balancing Quality, Consistency & Scalability of Starting Cell Lines through Strategic Selection

Choosing the right iPSC starting line is fundamental to influencing safety, efficacy, and manufacturability. Key factors such as donor selection, genomic stability, and differentiation potential must be carefully evaluated alongside evolving regulatory expectations. This session will explore best practices for optimizing cell line selection, balancing standardization with therapy-specific requirements.

Join this workshop to:

- Analyze the impact of donor variability on iPSC line performance, including how genetic differences can influence differentiation capacity and final therapeutic outcomes
- Address challenges in acquiring GMP-grade iPSC lines, focusing on overcoming cost and regulatory barriers
- Discuss strategies for optimizing starting iPSC lines, including isogenic lines or barcoded 'villages' to reduce variability
- Assess predictive assays for iPSC differentiation in various contexts, ensuring selected lines are suitable for specific therapeutic applications

Workshop Leaders

Annelise Bennaceur
Chief Scientific Officer
iPSirius

Benjamin Schwarz
Associate Director
Thymmune Therapeutics

Lunch Break & Networking — **12.00 - 1.00**

Workshop B — 1.00 - 4.00

Uniting the iPSC Community to Identify Opportunities for Harmonization in QC Testing & iPSC Differentiation

As the iPSC field evolves, standardization of QC testing and differentiation processes remains a critical challenge. This workshop will bring together key stakeholders to identify opportunities for harmonizing quality control measures and differentiation protocols across the iPSC industry.

Join this workshop to:

- Highlight how collaboration and industry-driven standardization can reduce inefficiencies and accelerate the development of iPSC-based products across clinical stages
- Identify commonalities between different iPSC platforms to enhance cross-functional learning and work towards standardizing procedures
- Discuss best practices to define critical quality attributes for iPSCs that can be agreed upon across multiple processes
- Explore different approaches to QC testing such as residual IPS, potency, and toxicology assays that can be harmonized

Workshop Leaders

Anastasia Shindyapina
Staff Scientist
Retro Biosciences

Panagiotis Douvaras
Head of CNS Biology
Retro Biosciences

Yanzheng Liu
Senior Director of Quality Control
Aspen Neuroscience

End of Workshop Day — **4.00**

Conference Day One
Wednesday, October 1

7.30 **Registration & Coffee**

8.20 **Opening Remarks**

Unlocking Investment & Expanding Patient Access for iPSC-Based Therapies

8.30 **Industry Leaders Fireside Chat: Understanding the Investment Landscape & Novel Opportunities in the iPSC Space**

An interactive panel discussion from the industry leaders of the field to set the scene on the iPSC therapy space. Ask your questions live to understand the expert's thoughts on key topics including:

- Key factors influencing investment in iPSCs, including tech advancements, novel data and regulatory changes
- Addressing risks in iPSC development and strategies for attracting investment
- Novel iPSC-based therapy areas, such as tissue regeneration and biotech-academic collaborations advancing the field

Daniel Friedman
Principal
Broad Oak Partners

Howard Federoff
Chief Medical Officer
Kenai Therapeutics

Nina Horowitz
Chief Executive Officer
Immunebridge

Alex Ng
Co-Founder & Chief Scientific Officer
GC Therapeutics

Sanjeev Luther
Chief Executive Officer
Ernexa Therapeutics

9.30 **From Bench to Bedside to Community: Ensuring Widespread Patient Access to iPSC-BasedTherapies**

Jeffrey Kordower
Professor
Arizona State University

- How can we develop iPSC-based therapies that integrate into current clinical practices and patient care pathways?
- Understanding the role of clinicians, surgeons, and healthcare systems in adapting to new therapies
- Critical Parameters for iPSC Development, getting therapies to the clinic and community

10:00 **Session Reserved for PBS Biotech**

10:30 **Morning Break & Speed-Networking**

Preclinical Track

Leveraging Genetic Engineering to Drive Success in iPSC-Derived Therapies

11:30 Engineering for Allo-Evasion to Maximize Post-Transplant Success

- Designing genetic edits to reduce immune recognition and prolong cell persistence
- Optimizing HLA modulation strategies for improved allo-evasion and graft survival
- Balancing immune evasion with safety to prevent uncontrolled cell persistence

Howard Federoff, Chief Medical Officer, **Kenai Therapeutics**

12:00 Enhancing Genetic Engineering Strategies to Maximize Potency in iPSC-Derived Cellular Therapies

- Optimizing genetic modification processes to enhance cell purity, potency, and functionality
- Engineering considerations to improve safety, survival, engraftment, and therapeutic effect

Nina Horowitz, Chief Executive Officer, **ImmuneBridge**

Process Development & CMC Track

Aligning GMP Standards with Process Innovation for a Faster Path to Clinic

11:30 Defining Considerations when Transitioning Processes & Cell Lines from RUO to GMP

- How do we demonstrate comparability when switching cell lines?
- Key strategies to manage costs associated with transitioning into GMP
- Optimizing raw material selection to align with GMP standards

Sherry Hikita, Project Director, Cell Therapy R&D, **Novo Nordisk**

Selecting the Right Platforms to Ensure High Quality Manufacturing at Scale

12:00 Exploring Consistent Cellular Transitions & Quality Aspects in 3D iPSC-Derived Cardiomyocyte Production

- How early differentiation dynamics affect the reproducibility and efficiency of cardiomyocyte induction
- Key aspects of iPSC maintenance and quality that support consistent cardiomyocyte differentiation

Naoyuki Tahara, Senior Scientist, **Orizuru Therapeutics**

Conference Day One
Wednesday, October 1

12:30 Roundtable Discussion: Engineering iPSCs with Purpose: What Genetic Edits will Actually Drive Clinical Impact?

- How are teams prioritizing which edits to persue - immuno-evasion, functional potency, or off-the-shelf applicability?
- What lessons can we learn from clinical data on engineered cell therapies that should guide iPSC editing strategies?

12:30 Session Reserved for Ajinomoto

AJINOMOTO

1:00 Lunch

Lonza

*Private lunch hosted by **Lonza**, please inquire with info@hansonwade.com for more information*

Starting on the Right Foot by Evaluating Reprogramming & Sources for Stem Cells

2:00 Harnessing Engineered iPSC-Derived Immuno-Modulatory Alpha Neutrophils for Immune Reconstitution & Cancer Therapy

- Exploring the potential of iPSC-derived alpha neutrophils to restore immune function in oncology and age-related diseases
- Strategies to leverage these cells for robust immune reconstitution following immunosuppressive treatments
- Evaluating therapeutic applications across cancer and chronic inflammation driven by immune decline with age

Mark Exley, Chief Scientific Officer, **Lift Biosciences**

2:00 Panel Discussion: Understanding the Current Barriers to Achieving Closed System Automated Manufacturing

- Discussing key hurdles such as cost, complexity of processes, and regulatory challenges when adopting new instruments
- What are some opportunities in iPSC manufacturing processes where automation can be introduced?

Allen Feng, Founder & Chief Scientific Officer, **HebeCell**

Jay Sorensen, Vice President of Manufacturing, **Stratus Therapeutics**

2:30 Roundtable Discussion: Identifying Factors Contributing to iPSC Genomic Instability

- Identifying factors that contribute to genomic instability in iPSCs and their impact on therapeutic outcomes
- Developing novel techniques to identify genomic instability at the level of iPSCs and derived cells
- Exploring strategies to mitigate genomic instability, including optimized reprogramming techniques and targeted genetic modifications

Ali Turhan, Chief Medical Officer, **iPSirius**

2:30 Updates on end-to-end manufacturing of iPSCs at RoslinCT: platforms for cell banking, genome editing, 2D seed trains to 3D bioreactors

- Genomic integrity of clinical-grade iPSC banks and pGMP gene editing options
- Optimization of iPSC expansion and bioreactor inoculation for closed system GMP manufacturing
- Points to consider in 3D expansion of iPSCs in Vertical Wheel Bioreactors

Barbara Ressler, Vice President of Manufacturing Process Sciences, **RoslinCT**

Ali Darkazalli, Principal Scientist Process Development, **RoslinCT**

3:00 Unlocking the Therapeutic Promise of Human Embryonic Stem Cells

- Evaluating the advantages of hESCs over iPSCs in terms of genetic stability, differentiation efficiency, and scalability
- Discussing trials using hESCs, easy derivation, low cost of hESC lines and patient-specific hESCs and SCNT

Allen Feng, Co-Founder, **HebeCell**

3:00 Comparing 2D Versus 3D Manufacturing Platforms to Ensure the Right Fit

- How do we determine if transitioning into 3D platforms is necessary?
- Demonstrating process comparability when scaling up to stir tanks and bioreactors
- Strategies to maintain visibility over cell lines in 3D culture

Lev Starikov, Senior Scientist Process Development, **Bluerock Therapeutics**

3:30 Afternoon Break & Poster Session

Conference Day One
Wednesday, October 1

Showcasing Pioneering Technologies Advancing the iPSC Based Therapies Field

Alex Ng
Co-Founder & Chief Scientific Officer
GC Therapeutics

4:30 **Rewriting the Rules of Differentiation: Driving iPSC Fate Through Transcription Factor-Powered Programming with TFome™**

- Leveraging transcription factors (TFs) to drive differentiation without relying on cell-external cues
- Achieving up to 99% efficiency in four days through a single-step, cost-effective approach
- Integrating AI and high-throughout experimentation to discover key TFs for scalable, precision-driven differentiation

Matt Buckley
Chief Executive Officer & Co-Founder
Theseus Therapies

5:00 **Going Beyond Neurons: Replacing the Third Element with iPSC Derived Cells**

- The history and future of iPSC-derived microglia therapies
- Considerations for large-scale transplants
- Preclinical vignettes across rare genetic and common neurodegenerative diseases

Catalent

5:30 **Session Reserved for Catalent**

Jack Li
Director of Process Development
Stratus Therapeutics

6:00 **Breaking Barriers in Blood Stem Cell Therapy: A Universal Solution for HLA-Mismatched Patients**

- Many patients with life-threatening blood disorders lack access to matched donors, limiting curative treatment options
- ST101 is a universal, off-the-shelf blood stem cell therapy that eliminates the need for HLA matching
- Using gene-edited iPSCs, ST101 enables immediate, scalable, and durable hematopoietic reconstitution—redefining accessibility to curative therapies

6:30 **End of Day One**

> "It's an amazing conference that covers both R&D and manufacturing perspectives of iPSC. The well organized program offers not only the opportunity to learn the cutting-edge technologies, but also the excellent networking opportunities with so many leaders"
>
> Instructor, **UCLA**, **2024 Attendee**

Conference Day Two
Thursday, October 2

7.45 **Check-in & Coffee**

Streamlining Regulatory Strategies & Advancing Cell Delivery for Successful iPSC Therapy Development

8.30 **Panel Discussion: Understanding Evolving Frameworks & Addressing Regulatory Expectations Towards iPSC Based Therapies**

- Exploring the challenges posed by regulatory inconsistencies between agencies and strategies to navigate evolving requirements for iPSC therapies
- Discussing best practices to propose new data, technologies and assays to regulators

Azadeh Golipour
Senior Vice President Head of Technical Operations
GC Therapeutics

Eric Law
CMC Regulatory Affairs
Century Therapeutics

Allen Feng
Co-Founder
HebeCell

Rajesh Thangapazham
Global Regulatory Strategy Lead
Vertex Pharmaceuticals

Eric Law
CMC Regulatory Affairs
Century Therapeutics

9.30 **Case Study: Discussing the Regulatory Pathway to Clinic**

- Highlighting the journey of advancing gene-edited iPSC therapies from preclinical to clinical trials, sharing lessons learned and insights on meeting regulatory and CMC expectations

Doris Taylor
Chief Executive Officer & Co-Founder
Organamet

10.00 **Refining the Path to Delivering Cells to Patients**

- Ensuring iPSC-derived cell delivery methods are accessible, viable, and adaptable to a range of clinical settings
- Applying lessons from iPSC based organ development to optimize trial design and prepare for future applications

10.30 **Morning Break & Networking**

Preclinical Track

Demonstrating Safety for iPSC-Derived Therapies to Ensure a Smooth Path to Clinic

11.30 Roundtable Discussion: Analyzing Different Approaches to Toxicology Assays

- Diving into different methods to conduct residual IPS assays and how to best present results to regulators
- Comparing and contrasting toxicology assays between different cell types

Anastasia Shindyapina, Staff Scientist, **Retro Biosciences**

Process Development & CMC Track

Enabling Scalable & Reliable Manufacturing of iPSC-Derived Cells for Broad Therapeutic Impact

11.30 Scalable Generation of PSC-derived Natural Killer Cells Utilizing Suspension Culture

ThermoFisher SCIENTIFIC

Conference Day Two
Thursday, October 2

Selecting the Right Conditions to Nurture Desired iPSC Differentiation

12.00 Accurately Recapitulating T-Cell Development for Autoimmune & Oncology Applications

- Strategies to mimic thymic selection and T-cell maturation *in vitro* to ensure functional and self-tolerant T-cell populations
- Tailoring iPSC-derived T-cell for tumor-specific or autoimmune-resistant profiles through precise developmental control
- Overcoming current challenges in achieving lineage specificity and scalability for clinical-grade T-cell products

Ran Jing, Instructor, **Harvard Medical School**, **Boston Children's Hospital**

12.00 Standardizing iPSC Differentiation to Improve Reproducibility in Manufacturing

- Overcoming heterogeneity and variability in large-scale differentiation processes
- Implementing robust quality control strategies to ensure batch-to-batch consistency
- Aligning differentiation protocols with GMP requirements for clinical translation

Jason Mills, Senior Director Process Development, **Century Therapeutics**

12.30 Lunch

1.30 Evaluating the Impact of Cell Culture Environments on iPSC Differentiation

- Highlighting the process of differentiating iPSCs to iMSCs
- Discussing how factors such as temperature, timing, culture media, nutrients, and more impact the behaviour of iPSC-derived cells

Robert Pierce, Chief Scientific Officer, **Ernexa Therapeutics**

Advancing Cell Characterization Techniques & Parameters for Validation of Processes

1.30 Defining Parameters to Assess the Quality of Desired End Cell Type

- Implementing strategies to validate the accuracy of cell differentiation
- Exploring morphological, molecular, and functional assays to confirm cell identity
- How can we evaluate the genomic stability of the final cell product?

Lina Sui, Senior Director Process & Analytical Development, **Sana Biotechnology**

2.00 Advanced Technologies for Engineering iPSC-Derived Tissues & Organs

- Cutting-edge biotechnologies for functional tissue and organ engineering
- Personalized biomaterials for engineering autologous iPSC-derived tissues
- 3D and 4D printing of personalized tissues and organs
- Integration of micro/nanoelectronics into engineered tissues to create cyborg and bionic organs

Tal Dvir, Professor & Co-Founder, **Tel Aviv University**, **Matricelf**

2.00 Finding the Right Balance when Monitoring iPSCs

- How often should differentiating cells be analyzed
- Are there any differentiation milestones that need to be observed?
- What needs to be observed at every point (morphology, marker expression, purity)?

Alla Amcheslavsky, Senior Scientist CMC Analytical Development, **Astellas Pharma**

2.30 Afternoon Break

Conference Day Two
Thursday, October 2

Leveraging iPSCs Beyond Cellular Therapies

Ali Turhan
Chief Medical Officer
iPSirius

3.00 **Advancing Cancer Modeling with iPSCs: Current Approaches & Opportunities**

- Modeling hereditary cancers using iPSC-derived cancer organoids
- Understanding novel signaling pathways in cancer progression
- Uncovering novel targets for drug and future cell therapies

Angelos Oikonomopoulos
Principal Scientist, Project Lead
Formerly BMS

3.30 **Harnessing iPSCs for Drug Development, Applications in Drug Screening & Hit Identification**

- Using iPSC-CM reporter lines for small molecule screening
- Effects of identified hits on gene expression and cardiomyocyte morphology

4.00 **Closing Remarks**

4.10 **End of the 5th iPSC Drug Development Summit**

> It's great to connect with scientists and leaders at the forefront of the pragmatic translation of iPSC research into therapeutics

Chief Executive Officer & Co-Founder, **Theseus Therapies**, **2025 Speaker**

> Participating in this meeting is a unique chance to engage with fellow innovators to exchange ideas that will shape the next generation of hematologic treatments and patient access models

Director of Process Development, **Stratus Therapeutics**, **2025 Speaker**

Partner With Us

5th Annual iPSC Drug Development Summit
September 30 – October 2, 2025
Boston, MA

From discovery and preclinical research to manufacturing, regulatory strategy, CMC and investment, the **5th iPSC Drug Development Summit** is your most comprehensive platform to engage with cross-functional stakeholders advancing iPSC-derived therapies toward the clinic and beyond.

This meeting uniquely brings together experts from across the iPSC therapy value chain spanning R&D, process development, regulatory affairs, and business development to openly discuss shared challenges and solutions for genetically stable, scalable, and clinically efficacious iPSC-derived therapies. With leading voices from **Aspen Neuroscience**, **Century Therapeutics**, **BlueRock Therapeutics**, **Novo Nordisk**, **Sana Biotech**, and **Kenai Therapeutics**, this is your opportunity to align on technical priorities and forge lasting, strategic partnerships across therapeutic areas.

Spotlight your solutions to an engaged and tight-knit audience to ensure you create intimate connections and accelerate partnerships

Build relationships with senior decision makers and stakeholders to drive your commercial and strategic goals

Establish your brand as the pioneers, discover success in recent clinical trials and pave the way for the next wave of off-the-shelf therapies

SENIORITY OF ATTENDEES*



- Chief/CXO: 44%
- President/VP: 10%
- Manager: 8%
- Scientist: 26%
- Other: 12%

TYPES OF COMPANIES ATTENDING*



- Drug Developer
- Service Provider
- Research Institute
- Others

*Statistics taken from 4th iPSC Drug Development & Manufacturing Summit

GET INVOLVED

Oliver Smare
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us

5th Annual iPSC Drug Development Summit
September 30 – October 2, 2025
Boston, MA

Expertise Partner

Catalent

FUJIFILM
Value from Innovation

Program Partners

Ajinomoto

PBS Biotech

Roslin CT

ThermoFisher Scientific

Hosting Partner

Lonza

Innovation Partner

Advanced Instruments

Exhibition Partner

bit bio

GET INVOLVED

Oliver Smare
Business Development Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.ipsc-therapies-summit.com/take-part/register/

Tel: +1 617 455 4188

Email: info@hansonwade.com

Analyze the latest data on the efficacy of iPSC derived therapies

Optimize your expansion and cell processes to maximize cell viability and volume

Engage with top trailblazers in the allogeneic space across the whole spectrum of specialties, from R&D all the way to regulatory experts

Drug Developer Pricing*	Register & Pay by Friday, July 11	On the Door Price
Conference + Workshop Day	$3,497 **(Save $700)**	$4,197
Conference Only	$2,599 **(Save $400)**	$2,999

Academic Pricing**	Register & Pay by Friday, July 11	On the Door Price
Conference + Workshop Day	$2,897 **(Save $700)**	$3,597
Conference Only	$2,199 **(Save $400)**	$2,599

Solution & Service Provider Pricing	Register & Pay by Friday, July 11	On the Door Price
Conference + Workshop Day	$4,497 **(Save $700)**	$5,197
Conference Only	$3,399 **(Save $400)**	$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Hilton Boston Logan Airport

One Hotel Drive, Boston, MA 02128

www.hilton.com/en/hotels/boslhhh-hilton-boston-logan-airport/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom